European Institute of Oncology (IEO) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
European Institute of Oncology (IEO) takes part in 13 sessions at ESMO 2026 in Madrid. Its program centres on ovarian and endometrial cancer, from platinum-resistant ovarian disease to molecular classification in endometrial cancer, and on EGFR-mutant and other gene-driven non-small cell lung cancer. Other sessions cover radiopharmaceutical therapy, locally advanced prostate cancer and mixed neuroendocrine tumours.
| Organization | ESMO 2026 Attendance |
|---|---|
European Institute of Oncology (IEO) Milan, Italy | |
Private cancer hospital and research institute in Milan, Italy, recognised by the Italian state as a research hospital. | Satellite Fri Oct 23 09:45–11:15 Satellite Fri Oct 23 09:45–11:15 MSD - Emerging Evidence and Treatment Integration in Ovarian and Endometrial Cancer Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 09:45–09:48 Welcome Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 09:58–10:18 Major Data Highlights and Clinical Implications for PROC Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 10:10–10:30 Tackling NSCLC Harboring Actionable Genomic Alterations Lung & thoracic cancers Satellite Fri Oct 23 10:23–10:38 Case‑based discussion on treatment selection and sequencing in ovarian cancer Gynaecological cancersBiomarkers & precision oncology Satellite Fri Oct 23 10:50–11:10 Keeping the Patient in the Center Lung & thoracic cancers Chair Fri Oct 23 13:30–15:00 Update on the mangement of endometrial cancer in the era of molecular classification Gynaecological cancers Chair Fri Oct 23 16:15–17:45 Rapid oral 1: Gynaecological cancers Gynaecological cancers Abstract Sat Oct 24 15:57–16:07 Invited Discussant LBA38 and 1240O Gynaecological cancers Chair Sat Oct 24 16:30–17:45 A multidisciplinary approach to Mixed Neuroendocrine-Non- neuroendocrine Neoplasms (MiNEN) Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 16:30–16:35 Presentation of case/condition Sarcoma, CNS, head & neck and rare cancers Satellite Sat Oct 24 18:55–19:15 Expanding the Reach – Novel Combinations and Non-Biomarker Selected Therapies Gynaecological cancers Satellite Sat Oct 24 19:35–19:50 Future Directions and Case-Based Application Gynaecological cancers Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers Satellite Sun Oct 25 13:27–13:52 Shaping long-term outcomes in first-line treatment for EGFR-mutant NSCLC Lung & thoracic cancers Chair Sun Oct 25 16:30–18:15 Presidential Symposium II Lung & thoracic cancersGastrointestinal cancers Talk Mon Oct 26 08:30–08:55 Optimising therapy for locally advanced prostate cancer Genitourinary cancers Chair Mon Oct 26 08:30–10:00 Proffered paper 2: NSCLC, metastatic Lung & thoracic cancers Satellite Mon Oct 26 18:45–19:15 Satellite Mon Oct 26 19:15–19:25 Satellite Mon Oct 26 19:25–19:40 Talk Tue Oct 27 09:20–09:40 Talk Tue Oct 27 11:40–12:00 |
Instantly find 20 buyers from European Institute of Oncology (IEO)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction